pharmacophore model for ATP-competitive inhibitors interacting with the active site of the EGFR proteintyrosinekinase and a putative binding mode of 4-anilinoquinazoline suggest that a salicylic acid function could serve as the pharmacophore replacement of a pyrimidine ring. Superpositions by CAMM of salicylanilides with the potent EGFR tyrosinekinaseinhibitor 4-[(3'-chlorophenyl)amino]-6,7-dimethoxyquinazoline